Ibrance and Hepatitis - a phase IV clinical study of FDA data

Summary:

Hepatitis is reported as a side effect among people who take Ibrance (palbociclib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Fulvestrant, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Hepatitis when taking Ibrance. It is created by eHealthMe based on reports of 104,340 people who have side effects when taking Ibrance from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

What is Hepatitis?

Hepatitis (inflammation of the liver) is found to be associated with 1,459 drugs and 1,524 conditions by eHealthMe. Check the latest studies of Hepatitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

104,340 people reported to have side effects when taking Ibrance.
Among them, 87 people (0.08%) have Hepatitis.

Among these 87 people:

How long have people been on Ibrance when they have Hepatitis? *

What is the gender of people who have Hepatitis when taking Ibrance? *

female: 98.8 %
male: 1.2 %

What is the age of people who have Hepatitis when taking Ibrance? *

What are other drugs people take besides Ibrance? *

What are other side effects people have besides Hepatitis? *

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 13 people, 14.94%
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 12 people, 13.79%
Hepatic Enzyme Increased: 10 people, 11.49%
Disease Progression: 8 people, 9.20%
Nausea (feeling of having an urge to vomit): 8 people, 9.20%
Thrombocytopenia (decrease of platelets in blood): 7 people, 8.05%
Hepatic Steatosis (fatty liver disease): 7 people, 8.05%
Neoplasm Progression (growth of tumour): 7 people, 8.05%
Abdominal Discomfort: 7 people, 8.05%
Weight Decreased: 7 people, 8.05%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 34 people, 39.08%
Breast Cancer: 20 people, 22.99%
Breast Cancer Female: 7 people, 8.05%
Pain: 3 people, 3.45%
Ovarian Cancer (cancer of ovary): 2 people, 2.30%
Nausea (feeling of having an urge to vomit): 2 people, 2.30%
Breast Cancer Stage Iv: 2 people, 2.30%
Type 2 Diabetes: 1 person, 1.15%
Rashes (redness): 1 person, 1.15%
Mucosal Inflammation (infection of mucous membrane): 1 person, 1.15%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrance and have Hepatitis?

- Check whether Hepatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrance:

Ibrance (104,434 reports)

Hepatitis treatments and more:

Hepatitis (31,197 reports)

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis:

Hepatitis (1,459 drugs)

Browse all the conditions that are associated with Hepatitis:

Hepatitis (1,524 conditions)

Related publications that referenced our studies

Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .
Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on palbociclib (the active ingredients of Ibrance) and Ibrance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.